Bevacizumab Administration and Surgery Guidelines
Pre-Surgery Waiting Period
- The National Comprehensive Cancer Network (NCCN) recommends an interval of at least 6 weeks (which corresponds to 2 half-lives of the drug) between the last dose of bevacizumab and any elective surgery, to minimize the risk of wound healing complications and bleeding in patients undergoing elective surgery 1
Post-Surgery Restart
- The NCCN guidelines suggest waiting at least 6-8 weeks after major surgery and until adequate wound healing before restarting bevacizumab, to ensure complete wound healing and minimize the risk of bleeding complications in patients who have undergone surgery 1
Surgical Risks and Considerations
- Patients who undergo surgery too soon after bevacizumab administration face increased risks of wound dehiscence, delayed wound healing, surgical site bleeding and hemorrhage, wound infections, and gastrointestinal perforation, highlighting the importance of careful timing and monitoring in patients receiving bevacizumab 1
Guideline Recommendations
| Source | Pre-Surgery Waiting Period | Post-Surgery Restart |
|---|---|---|
| NCCN 2024 | 6 weeks (42 days) | 6-8 weeks |
- The NCCN 2024 guidelines provide a clear direction for the management of bevacizumab administration and surgery, recommending a pre-surgery waiting period of at least 6 weeks and a post-surgery restart period of at least 6-8 weeks, to minimize the risk of complications in patients undergoing elective surgery 1